CHMFL-ABL-121

Cat. No.:	HY-119370
CAS No.:	2270879-07-5
Molecular Formula:	$C_{30}H_{31}F_3N_6OS$
Molecular Weight:	580.67
Target:	Bcr-Abl; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC_{50}s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively[1].	
IC_{50} & Target	ABL wt 2 nM (IC_{50})	ABL-T315I 0.2 nM (IC_{50})
In Vitro	CHMFL-ABL-121 dose-dependently inhibits BCRABL's auto-phosphorylation at Y245 site in K562 (EC_{50}<10 nM),MEG-01 (EC_{50} <10 nM) and KU812 (EC_{50}<30 nM) cells and also significantly blocks the phosphorylation of downstream signaling mediators STAT5, CrkL and ErK[1]. CHMFL-ABL-121 induces apoptosis and arrests cell cycle at G0/G1 phase[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Liu X, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem. 2018 Dec 5;160:61-81.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA